To include your compound in the COVID-19 Resource Center, submit it here.

China FDA approves Daklinza combos for HCV

Bristol-Myers Squibb Co. (NYSE:BMY) said China FDA approved Daklinza daclatasvir in combination with Sunvepra asunaprevir to treat HCV genotype 1b in patients with or

Read the full 249 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE